Phase 3 outcomes from NEJM SURMOUNT-1, SURPASS-2, STEP-1, and Lancet Orforglipron oral GLP-1 trials—plus hepatic dawn phenomenon physiology, 15-minute post-meal GLUT4 walks, and first-30-day Type 2 Diabetes remission protocols. Explore 704 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
No change in FBF was observed with SNP.
Gastric emptying AUC(0-300 min) was equivalent for liraglutide 1.8 and 3.0 mg, and for liraglutide versus placebo, whereas reductions in 1-h gastric emptying of 23% with liraglutide 3.0 mg and 13% with 1.8 mg versus placebo...
In comparison to amlodipine, telmisartan did not decrease the HOMA-IR.
The glucometabolic effects of efpeglenatide 6 mg QW and 16 mg QM were comparable to liraglutide.
There was no significant difference in treatment satisfaction between the groups.
Candesartan did not achieve similar improvements in these patients.
Dasiglucagon provided rapid reversal of hypoglycaemia in adults with type 1 diabetes.
The results of the present study suggest that pitavastatin affects FPG and HbA1c less than atorvastatin and rosuvastatin in patients with T2DM and concomitant high cholesterol.
These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action.
Consistent with adult phase 3 trials, dasiglucagon rapidly and effectively restored PG levels following insulin-induced low blood sugar in children and adolescents with T1DM, with an overall safety profile similar to glucagon.
Hypertensive patients with type 2 diabetes treated with amlodipine exhibited an improved pattern of pulse wave reflection in comparison with those treated with losartan.
Eighty healthy Chinese volunteers (89.9% male; mean age, 28.7 years) were randomized into cohort 1 (n = 40) and cohort 2 (n = 39; 1 volunteer withdrew before receiving study treatment).
Effects of liraglutide on weight loss are associated with delay in gastric emptying of solids; measurement of gastric emptying (eg, at 5 weeks of treatment) may be a biomarker of responsiveness and may help to select...
The GLP-1 analog treatment, compared to placebo, highly significantly raised the T max estimates of cerebral cortex from 0.72 to 1.1 umol/g/min, equal to T max estimates in healthy volunteers.
Gemigliptin add-on therapy may be more effective than metformin dose escalation in patients with T2DM insufficiently controlled using metformin and SGLT2 inhibitors, without safety concerns.
LOS + HCTZ did not influence UA metabolism as well as glucose metabolism, likely because of inhibitory action of losartan on URAT1, although TEL + HCTZ were accompanied with impairment of the UA metabolism and glucose metabolism.
However, comparing both groups at the end of treatment, no significant differences in metabolic and/or hormonal parameters could be detected.
These present results indicate that dapagliflozin can significantly reduce glucose, BMI, blood pressure and AHI, and improve hypoxemia during sleep and excessive daytime sleepiness, which thereby has potential as an effective...
Telmisartan reduced neointima volume; atherosclerosis progression 10 mm proximal and distal to the stented segment and baPWV independent of blood pressure, glucose and lipid control in hypertensive type 2 diabetes.
Functional liver or kidney damages were not observed for all patients.
Semaglutide did not improve executive function; results from secondary analyses suggested effects on specific domains of cognition.
ALO-PIO combination therapy during the early period exerts better blood sugar control than ALO single-drug treatment and excellency in glycemic variability than low-dose sulfonylurea therapy in uncontrolled, drug-naïve or...
These results suggest that increasing the dose of metformin improves serum MDA-LDL levels in type 2 diabetes.
However, the reduction in ET-1 levels was similar across groups, suggesting a comparable effect on endothelial function over 12 weeks.
The anti-inflammatory markers were reduced in both groups at 12 weeks without any statistically significant difference across groups.
Our main finding is that after initiating a SGLT2 inhibitor based therapy an exaggerated decline in mGFR was related with improved vascular compliance of large arteries reflecting the pharmacologic effects of SGLT2 inhibitor...
An adequately powered trial is warranted to evaluate the efficacy of these incentive structures for reducing weight.
Vildagliptin effectively improved glucose level with a significantly greater reduction in glycemic variability and low blood sugar than glimepiride in patients with T2DM ongoing metformin therapy.
In patients with type 2 DM, ezetimibe single-drug treatment significantly reduced LDL and NEFA, and improved peripheral microvascular endothelial dysfunction.
We conclude that losartan increases the serum HMW-adiponectin concentration and concurrently improves insulin sensitivity in subjects with IFG/IGT.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
